abemaciclib sold brand name verzenio among others medication treatment advanced metastatic breast cancers developed eli lilly acts cdk inhibitor selective designated breakthrough therapy breast cancer us food drug administration fda october september approved use united states fda treatment certain breast since september abemaciclib approved us adult patients hormone receptor hrpositive human epidermal growth factor receptor advanced metastatic breast cancer progressed taking therapy alters patients studies compared fulvestrant plus abemaciclib fulvestrant plus placebo breast cancer patients progressionfree survival abemaciclib therapy months average compared months placebo arm side effects occurred patients studies diarrhea nausea vomiting leukopenia low white blood cell count including neutropenia anemia low red blood cell count thrombocytopenia low platelet count stomach pain infections fatigue decreased appetite abemaciclib mainly metabolized liver enzyme inhibitors enzyme ketoconazole expected increase blood plasma concentrations conversely inducers lower plasma concentrations abemaciclib shown study like related drugs palbociclib ribociclib abemaciclib inhibits enzymes cyclindependent kinase cyclindependent kinase enzymes responsible phosphorylating thus deactivating retinoblastoma protein plays role cell cycle progression first gap synthesis blocking pathway prevents cells progressing phase thereby inducing apoptosis cell vitro analysis using cancer cell lines reported abemaciclib induces cell death characterized formation cytoplasmic vacuoles derived lysosomes result suggests may mechanism action inhibition cyclindependent oral intake absolute bioavailability highest blood plasma concentrations reached hours average range hours circulation abemaciclib bound plasma proteins substance mainly metabolized liver enzyme ndesethylabemaciclib lesser extent hydroxy derivatives another oxidative metabolite metabolites high plasma protein binding rates similar parent abemaciclib excreted mainly via feces small extent via urine elimination halflife hours successful trials pretreated metastatic breast cancer announced phase may phase ii december phase iii february abemaciclib approved fda september either combination fulvestrant monotherapy women hr advanced metastatic breast cancer progressed receiving endocrine abemaciclib approved adjuvant treatment hr nodepositive adjuvant breast cancer high risk recurrence march abemaciclib involved phase iii clinical trials abemaciclib phase ii clinical trials head neck squamous cell biliary tract brain kaposi metastatic renal cell mantle cell abemaciclib may synthesized four step manner using suzuki coupling followed amination final step reductive amination using leuckart httpsenwikipediaorgwikiabemaciclib